Welcome to our dedicated page for Scisparc news (Ticker: SPRC), a resource for investors and traders seeking the latest updates and insights on Scisparc stock.
SciSparc Ltd. (SPRC) is a clinical-stage pharmaceutical innovator developing cannabinoid-based therapies for neurological disorders while operating a consumer hemp products division. This page provides verified updates on both business segments, serving investors and stakeholders with essential news repository.
Access authoritative information on SPRC's clinical trial advancements, regulatory filings, and financial performance alongside developments in its hemp-derived product line. Content includes press releases detailing research milestones, partnership announcements, and strategic initiatives across therapeutic and consumer markets.
Key updates cover FDA communications, intellectual property developments, quarterly earnings disclosures, and operational expansions. All materials are curated to meet investor needs for decision-making clarity while maintaining compliance with financial reporting standards.
Bookmark this resource for streamlined access to SPRC's official announcements and analysis. Regularly updated content ensures stakeholders stay informed about the company's progress in pharmaceutical innovation and consumer market execution.
SciSparc (SPRC) has received renewal approval from the Israeli Medical Cannabis Agency for its clinical trial of SCI-210 in children with autism spectrum disorder (ASD). The 30-day approval will be extended pending final approval from the Israeli police department. The trial is a double-blind, randomized, placebo-controlled study at Soroka University Medical Center, involving 60 children aged 5-18 with ASD.
The study will evaluate SCI-210, a combination of CBD and CannAmide™, against standard CBD monotherapy over a 20-week treatment period. Primary efficacy metrics include the ABC-C parent questionnaire and CGI-I scale. The company plans to initially commercialize SCI-210 in Israel before expanding internationally, subject to regulatory approvals.
SciSparc (Nasdaq: SPRC) announced that AutoMax Motors, a company with which it has a pending merger agreement, received its first $13 million shipment of JAC Motors vehicles following regulatory approval for direct importation in Israel. This milestone comes after AutoMax signed distribution agreements with JAC Motors earlier in 2024. SciSparc provided financial support to AutoMax to facilitate the JAC Motors transaction. The merger agreement between SciSparc and AutoMax, signed in April 2024, would enable SciSparc's expansion into the automotive sector, subject to shareholder approval from both companies.
SciSparc (Nasdaq: SPRC) has signed an amendment to its non-binding letter of intent (LOI) to spin off its pharmaceutical portfolio through a reverse merger with Miza III Ventures Inc. (TSXV: MIZA.P). The deal values SciSparc's pharmaceutical assets at approximately US$11.6 million, while Miza's enterprise value is set at US$3.3 million.
The deadline for finalizing the definitive agreement has been extended to March 31, 2025, with transaction closing targeted for April 30, 2025. SciSparc would receive 63,300,000 Miza common shares and up to 48,000,000 contingent rights, resulting in a controlling stake of 75-84.53% in the merged entity.
The portfolio includes clinical trials for SCI-110 (Tourette syndrome and Alzheimer's) and SCI-210 (autism).
SciSparc (Nasdaq: SPRC) has received FDA approval to proceed with its Phase IIb clinical trials in the U.S. for SCI-110, a potential breakthrough treatment for Tourette Syndrome (TS) in adults. This approval comes just one month after the application submission, marking a significant milestone for the company. The trial will be conducted at three leading centers: Yale Child Study Center, Hannover Medical School, and Tel Aviv Sourasky Medical Center.
The study aims to evaluate the efficacy, safety, and tolerability of SCI-110 in adult patients aged 18-65 years. The primary efficacy objective is to assess tic severity change using the Yale Global Tic Severity Scale at weeks 12 and 26 compared to baseline. SciSparc's CEO, Oz Adler, emphasized the unmet medical need for TS management and highlighted the promising results from their Phase IIa trial, which showed an average tic reduction of 21% across the entire sample.
SciSparc (Nasdaq: SPRC) has signed a non-binding letter of intent (LOI) to sell its entire 52.73% ownership stake in MitoCareX Bio to a publicly-traded US company. The deal involves a two-phase transaction:
1. SciSparc will sell 27% of its MitoCareX shares for $700,000 in cash.
2. The remaining 73% will be exchanged for shares based on an $8 million valuation of the purchaser and a $5 million valuation of MitoCareX.
The LOI includes provisions for additional milestones that could increase the consideration from $5 million to $7 million. The MitoCareX valuation represents a 47% increase from SciSparc's initial investment. SciSparc's CEO, Oz Adler, stated that this agreement aligns with their strategy to enhance shareholder value.
SciSparc (Nasdaq: SPRC) has received FDA approval to proceed with its Phase IIb clinical trial for SCI-110, a potential Tourette Syndrome treatment. The trial will be conducted at three leading centers: Yale School of Medicine, Hannover Medical School, and Tel Aviv Sourasky Medical Center. The study aims to evaluate the efficacy, safety, and tolerability of SCI-110 in adult patients aged 18-65 years.
The randomized, placebo-controlled trial will assess tic severity changes using the Yale Global Tic Severity Scale at weeks 12 and 26 compared to baseline. SciSparc has already secured Institutional Review Board approvals from all three clinical sites and related federal administrations. This milestone reinforces SciSparc's ambition to become a leading provider of treatments for central nervous system disorders.
SciSparc (Nasdaq: SPRC) has submitted an Investigational New Drug application to the FDA for a phase IIb clinical trial of SCI-110, its proprietary treatment for Tourette Syndrome. The trial will be conducted at three leading centers: Yale Child Study Center, Hannover Medical School, and Tel Aviv Sourasky Medical Center. The company has already secured necessary approvals from institutional review boards and relevant health authorities.
The trial aims to evaluate the efficacy, safety, and tolerability of SCI-110 in adult patients aged 18-65 years. Participants will be randomized to receive either SCI-110 or a placebo. The primary efficacy objective is to assess tic severity change using the Yale Global Tic Severity Scale at weeks 12 and 26 compared to baseline. The safety objective focuses on monitoring adverse events in both treatment groups.
SciSparc (Nasdaq: SPRC) and Clearmind Medicine Inc. (Nasdaq: CMND) have announced the publication of an international patent application for a pioneering Ibogaine combination therapy. This innovative treatment aims to enhance safety and efficacy in mental health and addiction care. The patent application, filed under the Patent Cooperation Treaty, covers the combination of Ibogaine with N-Acylethanolamines.
Ibogaine, derived from the Tabernanthe iboga shrub, has shown potential in treating various substance use disorders. The collaboration between SciSparc and Clearmind focuses on developing therapies that combine psychedelic molecules with N-acylethanolamines, including Palmitoylethanolamide. To date, thirteen patents related to this collaboration have been filed by Clearmind in the U.S. and other global jurisdictions.
SciSparc (Nasdaq: SPRC) has advanced an additional $1.85 million loan to AutoMax Motors , bringing the total bridge loan amount to $4.25 million. This follows a second amendment to their Bridge Loan Agreement from January 14, 2024. In exchange, AutoMax provided a first-ranking fixed charge security interest on shares of its subsidiary, AutoMax Leasing This loan fulfills the Closing Financing requirement outlined in their April 10, 2024 Merger Agreement.
Notably, AutoMax Leasing has signed a direct import agreement with JAC Motors, a major Chinese automobile manufacturer. This partnership could potentially expand AutoMax's vehicle offerings and market presence.
SciSparc (Nasdaq: SPRC) and Clearmind Medicine Inc. have announced the publication of an international patent application for an innovative MDMA-based combination treatment. This collaboration aims to enhance the safety and efficacy of mental health and addiction treatments by combining MDMA with N-Acylethanolamines, including Palmitoylethanolamide (PEA).
The partnership has already resulted in thirteen patent applications filed with the U.S. Patent and Trademark Office and other global jurisdictions. SciSparc's CEO, Oz Adler, emphasized that this approach may address FDA concerns regarding MDMA safety, potentially overcoming regulatory barriers and unlocking MDMA's full potential in clinical settings.